Subsequent multivariate analysis revealed that combined LRTs modality with sorafenib remained as the independent predictor for the better OS [adjusted hazard ratio (HR) 0.5, 95% CI 0.3–0.8, P = 0.002], together with Child-Pugh class (adjusted HR 1.8, 95% CI 1.2–2.5, P < 0.001), tumor size (adjusted HR 1.5, 95% CI 1.1–2.3, P = 0.030), EHS and/or RNI (adjusted HR 1.7, 95% CI 1.2–2.4, P = 0.001), AFP level (adjusted HR 1.6, 95% CI 1.1–2.1, P = 0.002), and the cumulative dose of sorafenib (transformed by natural logarithm) (adjusted HR 0.5, 95% CI 0.4–0.6, P < 0.001 ) (Table 2). The gene discussed is AFP; the disease is neoplasm.